Passive immunization with influenza haemagglutinin specific monoclonal antibodies

Rudraraju, Rajeev; Subbarao, Kanta

doi:10.1080/21645515.2018.1489947

Cited by 5 publications

(6 citation statements)

References 77 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…after exposure to an infected individual). 24,53,54 In these cases, the relative costs and benefits of mAb use for prevention will need to be compared to other interventions that can potentially be used in this situation. With highly potent mAbs and a long serum half-life, 2 mg/kg is a reasonable estimate for a two mAb dose, suggesting 0.24 metric tons/million users would be required for a single-use product.…”

Section: Influenzamentioning

confidence: 99%

Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing

Whaley

Zeitlin

2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This review focuses on the emerging monoclonal antibody market for infectious diseases and the metric ton scale manufacturing requirements to meet global demand. Increasing access to existing antibodybased products coupled with the unmet need in infectious disease will likely exceed the current existing global manufacturing capacity. Further, the large numbers of individuals infected during epidemics such as the ongoing COVID-19 pandemic emphasizes the need to plan for metric ton manufacturing of monoclonal antibodies by expanding infrastructure and exploring alternative production systems.

show abstract

Section: Influenzamentioning

confidence: 99%

Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing

Whaley

Zeitlin

2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…In that regard, treatment by passive immunization could be a suitable option as an aid to vaccination, since it has had an important role in the control of multiple diseases, including the pandemic caused by the H1N1 influenza virus ( 17 – 19 ). This approach has already been applied in severe COVID-19 patients where plasma from convalescent patients was used, leading to the reduction of viremia and a substantial clinical improvement ( 20 , 21 ).…”

Section: Introductionmentioning

confidence: 99%

Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19

Agurto-Arteaga

Poma-Acevedo²,

Rios-Matos³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Within the framework of the current COVID-19 pandemic, there is a race against time to find therapies for the outbreak to be controlled. Since vaccines are still tedious to develop and partially available for low-income countries, passive immunity based on egg-yolk antibodies (IgY) is presented as a suitable approach to preclude potential death of infected patients, based on its high specificity/avidity/production yield, cost-effective manufacture, and ease of administration. In the present study, IgY antibodies against a recombinant RBD protein of SARS-CoV-2 were produced in specific-pathogen-free chickens and purified from eggs using a biocompatible method. In vitro immunoreactivity was tested, finding high recognition and neutralization values. Safety was also demonstrated prior to efficacy evaluation, in which body weight, kinematics, and histopathological assessments of hamsters challenged with SARS-CoV-2 were performed, showing a protective effect administering IgY intranasally both as a prophylactic treatment or a post-infection treatment. The results of this study showed that intranasally delivered IgY has the potential to both aid in prevention and in overcoming COVID-19 infection, which should be very useful to control the advance of the current pandemic and the associated mortality.

show abstract

“…Dimeric secretory IgA antibodies provide most protection in the upper respiratory tract 14 . IgG1 is dominant in the lower respiratory tract, which is important for preventing influenza pneumonia 4 , 12 . In general, high-affinity neutralizing antibodies confer better protection than low-affinity neutralizing antibodies and non-neutralizing antibodies 9 , 10 , 12 , 15 .…”

Section: Introductionmentioning

confidence: 99%

“…IgG1 is dominant in the lower respiratory tract, which is important for preventing influenza pneumonia 4 , 12 . In general, high-affinity neutralizing antibodies confer better protection than low-affinity neutralizing antibodies and non-neutralizing antibodies 9 , 10 , 12 , 15 . Neutralizing anti-stem antibodies and non-neutralizing antibodies have indirect antiviral effects via FcR-mediated effector functions and complement-mediated lysis for decreasing viral spread and attenuating disease 5 – 8 , 16 , 17 .…”

Section: Introductionmentioning

confidence: 99%

Low quality antibody responses in critically ill patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection

Guo

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Although some adults infected with influenza 2009 A(H1N1)pdm09 viruses mounted high hemagglutination inhibition (HAI) antibody response, they still suffered from severe disease, or even death. Here, we analyzed antibody profiles in patients (n = 31, 17–65 years) admitted to intensive care units (ICUs) with lung failure and invasive mechanical ventilation use due to infection with A(H1N1)pdm09 viruses during 2009–2011. We performed a comprehensive analysis of the quality and quantity of antibody responses using HAI, virus neutralization, biolayer interferometry, enzyme-linked-lectin and enzyme-linked immunosorbent assays. At time of the ICU admission, 45% (14/31) of the patients had HAI antibody titers ≥ 80 in the first serum (S1), most (13/14) exhibited narrowly-focused HAI and/or anti-HA-head binding antibodies targeting single epitopes in or around the receptor binding site. In contrast, 42% (13/31) of the patients with HAI titers ≤ 10 in S1 had non-neutralizing anti-HA-stem antibodies against A(H1N1)pdm09 viruses. Only 19% (6/31) of the patients showed HA-specific IgG1-dominant antibody responses. Three of 5 fatal patients possessed highly focused cross-type HAI antibodies targeting the (K130 + Q223)-epitopes with extremely low avidity. Our findings suggest that narrowly-focused low-quality antibody responses targeting specific HA-epitopes may have contributed to severe infection of the lower respiratory tract.

show abstract

Passive immunization with influenza haemagglutinin specific monoclonal antibodies

Cited by 5 publications

References 77 publications

Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing

Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing

Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19

Low quality antibody responses in critically ill patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection

Contact Info

Product

Resources

About